Clinical trials: Dermatologic Diseases
Cutaneous Leishmaniasis
Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis
Current standard therapies with chemotherapy (CT) for Cutaneous Leishmaniasis (CL) are expensive, toxic/allergenic, frequently ineffective, burdensome, and often unavailable.
- Trial name
- HECT (NCT01277796)
- Testing
- Heat pack conduction-heat therapy
- Sponsor
- Universidad Peruana Cayetano Heredia
Margin Assessment, Breast Cancer
Spectral Cancer Tissue Recognition - I
This analytical performance study aims to validate the SPCTRone system for use in breast conserving surgery of breast cancer patients.
- Trial name
- SPCTR-I (NCT07459062)
- Where
- 2 sites in Netherlands
- Volunteers
- 100 people
- Sponsor
- SPCTR
Breast Cancer
Nanogen Pegfilgrastim (Pegcyte) PK/PD Clinical Study in Breast Cancer Patients
Breast cancer patients scheduled to receive myelosuppressive chemotherapy (AC regimen) will be enrolled in this study. Eligible patients receive single SC injection of pegcyte or neulastim 24 hours after administration of…
- Trial name
- NCT03376503
- Testing
- Pegfilgrastim
- Where
- Vietnam
- Volunteers
- 24 people
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
Breast Cancer
Multi-Beam Intensity-Modulated Radiation Therapy for Node-Positive Breast Cancer
This study is being performed to understand the safety of a new radiation treatment called "Multi-Beam Intensity Modulated Radiation Therapy" ( IMRT).
- Trial name
- NCT01127373
- Testing
- Multi-Beam Intensity-Modulated Radiation Therapy, BreastQ questionnaire-
- Where
- 7 sites in United States
- Volunteers
- 116 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acne Vulgaris
Bioequivalence Study of Clindamycin Gel 1% in Treatment of Acne Vulgaris
This is a randomized, double-blind, multiple-site, placebo-controlled, parallel-group study, designed to compare the efficacy and safety of generic Clindamycin 1% gel (Akorn), and the marketed product Clindamycin 1% gel…
- Trial name
- NCT03522441
- Testing
- Clindamycin 1% Gel
- Where
- 12 sites in United States, Belize
- Volunteers
- 1,125 people
- Sponsor
- Akorn, Inc.
Lichen Planopilaris, Frontal Fibrosing Alopecia
Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
Oral naltrexone was initially FDA approved to treat opioid use disorder and alcohol dependence at doses from 50-100mg/day. At lower doses of 1-5mg/day, naltrexone has been used off-label with success in treatment of several…
- Trial name
- NCT04409041
- Testing
- Low-Dose Naltrexone
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Oral Mucosal Disease
Clinical Research Core Dental Screening Protocol
This study will screen patients for eligibility in studies sponsored by the Craniofacial Genetics Section (HCGS), the Clinical Research Core (CRC), and other branches located within the National Institute of Dental and…
- Trial name
- NCT00090818
- Where
- United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- National Institute of Dental and Craniofacial Research (NIDCR)
Melanoma
Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom
The purpose of this study is to describe the first-line therapy landscape for patients with advanced melanoma and to describe clinical outcomes and healthcare resource utilization in a subset of treatment-naïve patients who…
- Trial name
- NCT03448497
- Testing
- Non-interventional
- Where
- United Kingdom
- Volunteers
- 333 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Chemotherapy Effect
Chidamide in Combination With Vincristine Metronomic Chemotherapy for Advanced Triple-negative Breast Cancer
The mechanism of action of cidabenamide and the advantages of vincristine metronomic chemotherapy make it possible to combine the two drugs.
- Trial name
- NCT05747313
- Testing
- Chidamide
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Education, Nursing
The Effect of Mobile Augmented Reality Application on Nursing Students' Knowledge Skills and Motivation
The aim of this study was to examine the effects of a mobile augmented reality application on nursing students' knowledge, skills, and motivation regarding pressure injuries.
- Trial name
- NCT06675760
- Testing
- The intervention group
- Where
- Turkey (Türkiye)
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Izmir University of Economics
Breast Cancer
Peer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors
This randomized clinical trial studies peer navigator education in improving survivorship care in African American breast cancer survivors.
- Trial name
- NCT01450020
- Testing
- educational intervention, questionnaire administration, counseling intervention
- Where
- United States
- Volunteers
- 145 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Plaque Psoriasis
Efficacy Study on Dimethyl Fumarate to Treat Moderate to Severe Plaque Psoriasis
This multicenter, randomised, double-dummy, Fumaderm® and placebo-controlled, parallel-group study will compare the efficacy and safety of 500 mg of FP187 (250 mg twice daily) compared to 720 mg Fumaderm® (240 mg three times…
- Trial name
- NCT01815723
- Testing
- FP187, Dimethyl fumarate
- Where
- Canada
- Sponsor
- Forward-Pharma GmbH
Unintentional Ingestion of Prescriptions Within Vials and Blisters
Visual Distraction as a Means of Enhancing Child Resistance
Unintentional poisonings of children continues to be a major issue in the US. According to a study conducted by Cincinnati Children's Hospital Medical Centers, during the period from 2001-2008, emergency room visits for children…
- Trial name
- VDCR (NCT01859780)
- Testing
- Visual distractor
- Where
- 3 sites in United States
- Volunteers
- 229 people, healthy volunteers welcome
- Sponsor
- Michigan State University
Onchocerciasis
A Pharmacokinetic and Safety Study of Moxidectin to Identify an Optimal Dose for Treatment of Children 4 to 11 Years
The primary purpose of this study is to determine a dose of moxidectin for children 4 to 11 years that is equivalent to an 8 mg dose administered for treatment of onchocerciasis in people 12 years and over.
- Trial name
- NCT03962062
- Testing
- Moxidectin
- Where
- Ghana
- Volunteers
- 36 people
- Sponsor
- Medicines Development for Global Health
Melasma
EFFICACY and TOLERABILITY of TESTED FORMULA VS. HYDROQUINONE 4% in the TREATMENT of FACIAL MELASMA
This study aims at assessing the non-inferiority of tested formula facial serum (2039125 03) versus hydroquinone 4% over 3 months for treatment and then 3 months for maintenance ofwomen subjects presenting facial melasma.
- Trial name
- NCT06787846
- Testing
- Experimental: Group TP, Active Comparator: Group HQ: Hydroquinone 4%
- Where
- Brazil
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Cutaneous Melanoma
Minimal SN Tumor Burden
The purpose of this registry is to collect data in order to discover whether melanoma patients with minimal SN tumor burden should undergo a complete lymph node dissection (CLND) or not.
- Trial name
- Minitub (NCT01942603)
- Where
- 22 sites in Belgium, France and 8 more
- Volunteers
- 296 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Triple Negative Breast Cancer, Endometrial Cancer
ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma
Background: The new drug ONC201 have been shown to kill breast cancer and endometrial cancer cells in the laboratory. The exact mechanism of action is not completely clear yet, but the ONC201 destroys the mitochondria inside the…
- Conditions
- Triple Negative Breast Cancer, Endometrial Cancer, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Trial name
- NCT03394027
- Testing
- ONC201
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Menopause, Normal Physiology
Premenopausal Hormone Concentrations in a Population of Women at Very Low Risk of Breast Cancer
Background: Incidence of breast cancer is very low in Mongolia (6.6/100,000), especially in rural areas. Over the past 15 years, there has been considerable economic growth in Mongolia, resulting in migration to urban centers…
- Trial name
- NCT00860886
- Where
- Mongolia
- Volunteers
- 412 people
- Sponsor
- National Cancer Institute (NCI)
Giant Cell Arteritis
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab
Two recent RCTs showed the ability of tocilizumab to induce and maintain remission of giant cell arteritis. Both studies used the dosing schemes for Rheumatoid Arthritis (i.e. 8mg/kg bodyweight i.v.
- Trial name
- GUSTO (NCT03745586)
- Testing
- Tocilizumab, Glucocorticoids
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.